The Global Molecular Quality Controls Market size is expected to reach $259. 4 million by 2028, rising at a market growth of 6. 6% CAGR during the forecast period. Molecular quality controls are used to assess the performance of molecular tests like leukocyte reduced apheresis platelet (LRAP) units, virus load assays, pathogen detection, and healthcare-associated infections (HAIs) such as pneumonia and urinary tract infections, among others.
New York, June 17, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Molecular Quality Controls Market Size, Share & Industry Trends Analysis Report By Analyte Type, By Application, By Product, By End User, By Regional Outlook and Forecast, 2022 – 2028" - https://www.reportlinker.com/p06283449/?utm_source=GNW
For research and clinical laboratories, blood diagnostic centers, and IVD makers, these products are primarily focused on quality control, defect detection, and validation panels to aid in the installation and monitoring of assay-kit lot performance.
According to the World Health Organization, early detection and treatment of cancer can avert 30-50 percent of cancer-related deaths. In this case, personalized medicine appears to be the most effective alternative for addressing diseases that aren’t well-known for responding well to current therapies or cures. According to research provided by the PMC (Personalized Medicine Coalition), personalized medicines accounted for only 5% of novel FDA-approved molecular entities in 2005, but more than 25% in 2016. Furthermore, 42% of all compounds in the pipeline and 73% of oncology compounds have the potential to be individualized therapies. Biopharmaceutical companies’ R&D investments in personalized pharmaceuticals have nearly doubled in the last five years, according to the PMC, and are predicted to expand by 33% in the next few years. Biopharmaceutical researchers estimate a 69% increase in the number of individualized medications in development over the next five years, according to the same survey.
The COVID-19 outbreak had a negative impact on various business domains. Lockdowns stemming from the COVID-19 pandemic compelled to postpone medical appointments, reducing the number of tests performed and reagent sales. However, as governments increasingly loosen travel restrictions, there is a rebound in testing numbers. With the COVID-19 pandemic, dealing with contagious diseases has become a major medical concern around the world. Aside from vaccinations and therapeutic medications, there is an increasing demand for more accurate and simple testing technologies, as well as the proliferation of testing structures. This is bound to result in an increase in the demand for molecular quality control in the near future. As governments of various countries and health professionals face unprecedented problems, COVID-19 has had an impact on the regulatory environment and practices.
Market Growth Factors
The Rising Number of Accredited Clinical Laboratories
Clinical laboratories have proven to be one of the most important components of the modern healthcare value chain. Clinical laboratory tests have aided not only in the diagnosis of disease but also in the monitoring of therapy efficacy, and thus their demand has grown among the people. Clinical laboratories all around the world are attempting to gain accreditation on a national and international level in order to provide more dependable and better laboratory services. Molecular diagnostic laboratories undertake more complicated tests, are subject to stricter regulatory criteria, and are subject to a higher level of regulatory control.
High demand for Independent Controls and Multi-Analyte Control
Since they are manufactured independently of the instrument, reagents, and calibrators, independent controls are expected to have the largest market share in the molecular quality controls market due to their highly accurate, impartial, and independent assessment of a testing system or method performance test results in a short time with the highest sensitivity rate. Furthermore, a sharp increase in the usage of these products among third-party independent quality controls is likely to boost the market, owing to advantages such as a wide range of applications and lower operational costs.
Market Restraining Factors
Evolving Regulatory Framework
Regulatory and regulatory standards for in vitro diagnostics (including molecular diagnostics), generally known as IVD, are growing more stringent in the United States and Europe. In the United States and Europe, regulatory and legal criteria for including molecular diagnostics are getting more stringent as well. As a result, any changes to the device will necessitate the creation of new guidance manuals. IVD products are defined and regulated in the United States under 21 CFR 809, the same rules that apply to medical devices. New FDA guidance materials have been released by the FDA. Device manufacturers must file a 510(k) application to the US Food and Drug Administration for any future modifications to a device.
Analyte Type Outlook
Based on Analyte Type, the market is segmented into Single-analyte Controls and Multi-analyte Controls. The multi-analyte segment witnessed a significant revenue share in the molecular quality controls market in 2021. As a result of technological advancements, new multi-analyte and multi-instrument controllers have been developed. Clinical laboratories can save money by combining many instrument-specific controls into a single control. Furthermore, by removing the need for separate QC processes for each analyte, these controls save time. Due to the widespread availability of such molecular quality controls for infectious disease diagnostics and other uses, the market growth is likely to accelerate in the near future.
Based on Application, the market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. The infection diseases diagnostics segment acquired the largest revenue share in the molecular quality controls market in 2021. The advent of sophisticated assays for infectious diseases, a significant increase in the prevalence of infectious diseases, and increased awareness in the medical community about the efficient use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases are all factors contributing to this segment’s size.
Based on Product, the market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). The instrument-specific controls segment witnessed a substantial revenue share in the molecular quality controls market in 2021. Clinical laboratories are able to save money by combining multiple instrument-specific controls into a single control. Furthermore, by removing the need for separate QC procedures for each analyte, these controls save time.
End User Outlook
Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. The diagnostic laboratories segment acquired the largest revenue share in the molecular quality controls market in 2021. The number of accredited diagnostic laboratories is expected to increase in the coming years, providing potential prospects. Due to the increased need for molecular quality control, growing adoption of QC techniques, rising occurrences of regulatory actions, and rising expenditure on molecular diagnostics, the diagnostic laboratories segment is an important segment in the market. Clinical Laboratory Improvement Amendments (CLIA) were introduced by the Centers for Medicare & Medicaid Services, and they have been instrumental in increasing the rate of adoption of Molecular Quality Control procedures in clinical laboratories.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America acquired the largest revenue share in the molecular quality controls market in 2021. It is due to the substantially developed healthcare systems in the United States and Canada, the existence of many leading molecular quality control product manufacturers in the region, and easy access to technologically advanced products.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
Strategies deployed in Molecular Quality Controls Market
Jul-2021: Bio-Rad Laboratories entered into a partnership with Seegene, a key player in the multiplex molecular diagnostics market. The partnership aimed at the development and commercialization of infectious disease molecular diagnostic products. In addition, Seegene would offer diagnostic tests for use on Bio-Rad’s CFX96 Dx Real-Time PCR System for U.S. markets pending clinical development and clearance from The U.S. Food & Drug Administration (FDA).
Jul-2020: Roche Diagnostics unveiled the cobas prime Pre-analytical System, a system that minimize repetitive manual tasks related to processing the large number and wide range of sample tubes, vials, and containers observed in modern molecular labs. This system offers efficient automation for regular, high-quality pre-analytics, which eventually results in greater confidence in results from downstream instruments.
Mar-2020: Thermo Fisher Scientific introduced Thermo Scientific AcroMetrix Coronavirus 2019 (COVID-19) RNA Control, an updated quality control product to monitor and validate COVID-19 molecular diagnostics tests. This control was designed as a synthetic RNA, non-infectious control.
Mar-2020: Microbiologics released a SARS-CoV-2 IVD control, a novel IVD product within its Helix EliteTM line of molecular controls. The product is designed to deliver quality control measures for the development, verification, and validation of diagnostic tests while having the accuracy and ease of use of the Helix EliteTM line. It is created for extended use and flexibility to catch up to the lightning speed of high-volume testing.
Oct-2018: Grifols received FDA approval for its ID CORE XT molecular diagnostic test. The approval was given to it for its use in in-vitro diagnostic (IVD) usage in the United States. Patients who need continual transfusions including individuals with hemoglobinopathies like thalassemia and sickle-cell disease will be benefited from the ID CORE XT kit.
Scope of the Study
Market Segments covered in the Report:
By Analyte Type
• Single-analyte Controls
• Multi-analyte Controls
• Infectious Diseases Diagnostics
• Oncology Testing
• Genetic Testing
• Independent Controls
• Instrument-specific Controls
o DNA Sequencing & NGS
By End User
• Diagnostic Laboratories
• IVD Manufacturers & CROs
• Academic & Research Institutes
• North America
o Rest of North America
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
• Grifols, S.A
• Abbott Laboratories
• Quidel Corporation
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Seegene, Inc.
• Randox Laboratories Limited
• F. Hoffmann-La Roche Ltd.
• Bio-Techne Corporation
• Microbiologics, Inc.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
Read the full report: https://www.reportlinker.com/p06283449/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001